{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:03:06Z","timestamp":1760266986143,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Medical Research"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.arcmed.2009.08.005","type":"journal-article","created":{"date-parts":[[2009,10,22]],"date-time":"2009-10-22T08:57:19Z","timestamp":1256201839000},"page":"471-477","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV"],"prefix":"10.1016","volume":"40","author":[{"given":"Vicente","family":"Madrid-Marina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirvis","family":"Torres-Poveda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"L\u00f3pez-Toledo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Garc\u00eda-Carranc\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arcmed.2009.08.005_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib2","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2009.08.005_bib3","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ijc.10735","article-title":"Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3,091 women","volume":"102","author":"Bory","year":"2002","journal-title":"Int J Cancer"},{"key":"10.1016\/j.arcmed.2009.08.005_bib4","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1093\/jnci\/87.11.796","article-title":"Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group","volume":"87","author":"Bosch","year":"1995","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.arcmed.2009.08.005_bib5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJM199802123380703","article-title":"Natural history of cervicovaginal papillomavirus infection in young women","volume":"338","author":"Ho","year":"1998","journal-title":"N Engl J Med"},{"issue":"suppl 10","key":"10.1016\/j.arcmed.2009.08.005_bib6","doi-asserted-by":"crossref","first-page":"K1","DOI":"10.1016\/j.vaccine.2008.05.064","article-title":"Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia","volume":"26","author":"Bosch","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib7","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1128\/jcm.33.8.2058-2063.1995","article-title":"Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts","volume":"33","author":"Greer","year":"1995","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib8","unstructured":"FDA. Product approval information\u2014licensing action [package insert]. Gardasil (quadrivalent human papillomavirus types 6,11,16,18). 2007 29\/06\/2009]; Available at: http:\/\/www.fda.gov\/cber\/label\/HPVmer060806LB.pdf"},{"key":"10.1016\/j.arcmed.2009.08.005_bib9","unstructured":"Cervarix\u00ae U.S. regulatory update. 30 March 2009 [cited 2009 June 29] (available at: <http:\/\/www.gsk.com\/media\/pressreleases\/2009\/2009_pressrelease_10038.htm)"},{"key":"10.1016\/j.arcmed.2009.08.005_bib10","unstructured":"EPARs for authorised medicinal products for human use. December 2008 [cited 2009 July 8] Available at: http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/cervarix\/cervarix.htm."},{"key":"10.1016\/j.arcmed.2009.08.005_bib11","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2009.08.005_bib12","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1056\/NEJMoa020586","article-title":"A controlled trial of a human papillomavirus type 16 vaccine","volume":"347","author":"Koutsky","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2009.08.005_bib13","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0042-6822(91)90772-4","article-title":"Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for\u00a0assembly of HPV virion-like particles","volume":"185","author":"Zhou","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.arcmed.2009.08.005_bib14","doi-asserted-by":"crossref","first-page":"12180","DOI":"10.1073\/pnas.89.24.12180","article-title":"Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic","volume":"89","author":"Kirnbauer","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2009.08.005_bib15","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1128\/cdli.4.2.122-126.1997","article-title":"Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women","volume":"4","author":"Viscidi","year":"1997","journal-title":"Clin Diagn Lab Immunol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib16","series-title":"Vaccines for the Prevention of\u00a0Cervical Cancer","first-page":"67","article-title":"Prophylactic HPV vaccines: preclinical and proof of principle studies","author":"Stanley","year":"2008"},{"key":"10.1016\/j.arcmed.2009.08.005_bib17","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1086\/320190","article-title":"A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers","volume":"183","author":"Evans","year":"2001","journal-title":"J Infect Dis"},{"key":"10.1016\/j.arcmed.2009.08.005_bib18","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.92.25.11553","article-title":"Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas","volume":"92","author":"Suzich","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.arcmed.2009.08.005_bib20","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib21","doi-asserted-by":"crossref","unstructured":"De Carvalho N, Roteli-Martins C, Teixeira J, et\u00a0al. Immunogenicity and safety of the HPV-16\/18 AS04-adjuvant vaccine up to 7.3 years. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden.","DOI":"10.1016\/j.vaccine.2010.07.007"},{"key":"10.1016\/j.arcmed.2009.08.005_bib22","doi-asserted-by":"crossref","unstructured":"Rowhani-Rahbar A, Mao C, Alvarez FB, et\u00a0al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden.","DOI":"10.1016\/j.vaccine.2009.07.027"},{"key":"10.1016\/j.arcmed.2009.08.005_bib23","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0140-6736(06)68439-0","article-title":"Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial","volume":"367","author":"Harper","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2009.08.005_bib24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1038\/sj.bjc.6603469","article-title":"High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6\/11\/16\/18 L1 virus-like particle vaccine through 5 years of follow-up","volume":"95","author":"Villa","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.arcmed.2009.08.005_bib25","doi-asserted-by":"crossref","first-page":"6844","DOI":"10.1016\/j.vaccine.2008.09.073","article-title":"HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine","volume":"26","author":"Joura","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.jadohealth.2007.02.015","article-title":"Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant","volume":"40","author":"Pedersen","year":"2007","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.arcmed.2009.08.005_bib27","doi-asserted-by":"crossref","first-page":"4931","DOI":"10.1016\/j.vaccine.2007.03.049","article-title":"Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6\/11\/16\/18 L1 virus-like particle (VLP) vaccine","volume":"25","author":"Olsson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib28","unstructured":"Hepburn HM, Seipel M, Scharz TF, et\u00a0al. Ex-vivo monitoring of memory T-cells four years after vaccination. In the 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden."},{"key":"10.1016\/j.arcmed.2009.08.005_bib29","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1016\/j.vaccine.2007.02.069","article-title":"Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine","volume":"25","author":"Fraser","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib30","series-title":"Vaccines for the Prevention of Cervical Cancer","first-page":"77","article-title":"Prophylactic HPV vaccination: current status","author":"Kitchener","year":"2008"},{"issue":"suppl 10","key":"10.1016\/j.arcmed.2009.08.005_bib31","doi-asserted-by":"crossref","first-page":"K53","DOI":"10.1016\/j.vaccine.2008.06.002","article-title":"An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results","volume":"26","author":"Schiller","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib32","unstructured":"Dillner J. Quadrivalent HPV (types 6\/11\/16\/18) vaccine efficacy against low-grade genital desease. In the 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden."},{"key":"10.1016\/j.arcmed.2009.08.005_bib33","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(07)60946-5","article-title":"Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial","volume":"369","author":"Paavonen","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.arcmed.2009.08.005_bib34","unstructured":"Paavonen J, Naud P, Salmer\u00f3n J, et\u00a0al. Final phase III efficacy analysis of cervarix in young women. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden."},{"key":"10.1016\/j.arcmed.2009.08.005_bib35","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1056\/NEJMoa061741","article-title":"Future II study group, Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions","volume":"356","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2009.08.005_bib36","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(05)70101-7","article-title":"Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial","volume":"6","author":"Villa","year":"2005","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib37","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1056\/NEJMoa061760","article-title":"Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases","volume":"356","author":"Garland","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arcmed.2009.08.005_bib38","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/17455057.4.6.595","article-title":"Human papillomavirus vaccines and vaccine implementation","volume":"4","author":"de Sanjos\u00e9","year":"2008","journal-title":"Womens Health (Lond Engl)"},{"issue":"suppl 10","key":"10.1016\/j.arcmed.2009.08.005_bib39","doi-asserted-by":"crossref","first-page":"K87","DOI":"10.1016\/j.vaccine.2008.05.003","article-title":"Introduction of human papillomavirus vaccines into developing countries\u2014international strategies for funding and procurement","volume":"26","author":"Andrus","year":"2008","journal-title":"Vaccine"},{"issue":"suppl 10","key":"10.1016\/j.arcmed.2009.08.005_bib40","doi-asserted-by":"crossref","first-page":"K29","DOI":"10.1016\/j.vaccine.2008.06.019","article-title":"Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries","volume":"26","author":"Cuzick","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib41","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/S0264-410X(00)00370-4","article-title":"Immunological analyses of human papillomavirus capsids","volume":"19","author":"Giroglou","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00705-006-0734-y","article-title":"Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31","volume":"151","author":"Fleury","year":"2006","journal-title":"Arch Virol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib43","unstructured":"Skinner RAD, Chow SN, Wheeler C, et\u00a0al. Cross-protective efficacy of Cervarix against oncogenic HPV types beyond HPV-16\/18. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden."},{"key":"10.1016\/j.arcmed.2009.08.005_bib44","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1086\/597309","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16\u201326 years","volume":"199","author":"Wheeler","year":"2009","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.arcmed.2009.08.005_bib45","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.arcmed.2009.08.005_bib46","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1086\/597308","article-title":"Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types","volume":"199","author":"Herrero","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.arcmed.2009.08.005_bib47","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/AOG.0b013e318191a54a","article-title":"Cervical cancer after human papillomavirus vaccination","volume":"113","author":"Beller","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.arcmed.2009.08.005_bib48","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/01.inf.0000253970.29190.5a","article-title":"Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial","volume":"26","author":"Reisinger","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.arcmed.2009.08.005_bib49","first-page":"457","article-title":"Syncope after vaccination\u2013United States, January 2005\u2013July 2007","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.arcmed.2009.08.005_bib50","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1503\/cmaj.080916","article-title":"Anaphylaxis following quadrivalent human papillomavirus vaccination","volume":"179","author":"Brotherton","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.arcmed.2009.08.005_bib51","first-page":"1","article-title":"Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"56","author":"Markowitz","year":"2007","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.arcmed.2009.08.005_bib52","first-page":"37","article-title":"WHO Papillomavirus Position Paper","volume":"84","year":"2009","journal-title":"Weekly Epidemiological Record"},{"issue":"suppl 11","key":"10.1016\/j.arcmed.2009.08.005_bib53","doi-asserted-by":"crossref","first-page":"L73","DOI":"10.1016\/j.vaccine.2008.05.027","article-title":"Determinants of human papillomavirus vaccine acceptability in Latin America and the Caribbean","volume":"26","author":"Winkler","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.arcmed.2009.08.005_bib54","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1590\/S0036-36342009000400011","article-title":"Recomendaciones para la definici\u00f3n de la pol\u00edtica de vacunaci\u00f3n contra el virus del papiloma en M\u00e9xico","volume":"51","author":"Lazcano-Ponce","year":"2009","journal-title":"Salud Publica Mex"},{"key":"10.1016\/j.arcmed.2009.08.005_bib55","unstructured":"Paavonen J, ed. Final phase III efficacy analysis of Cervarix in young women. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden."},{"key":"10.1016\/j.arcmed.2009.08.005_bib56","unstructured":"Dillner J, ed. HPV vaccines trials and results. 25th International Papillomavirus Conference Clinical and Educational Workshop. May 8-14, 2009; Malm\u00f6, Sweden."}],"container-title":["Archives of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844090900143X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S018844090900143X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T19:37:55Z","timestamp":1759261075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S018844090900143X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":56,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S018844090900143X"],"URL":"https:\/\/doi.org\/10.1016\/j.arcmed.2009.08.005","relation":{},"ISSN":["0188-4409"],"issn-type":[{"type":"print","value":"0188-4409"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advantages and Disadvantages of Current Prophylactic Vaccines Against HPV","name":"articletitle","label":"Article Title"},{"value":"Archives of Medical Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arcmed.2009.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 IMSS. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}